Chimeric Therapeutics Ltd. (AU:CHM) has released an update.
Chimeric Therapeutics Limited has announced a change in the holdings of director Mr. Phillip Hains, where all of his 142,860 CHMO options expired on March 31, 2024, without any being acquired or sold. This leaves Mr. Hains with an indirect interest of 10,326,028 shares in the company. The notice underscores no new interests in contracts or securities were acquired or disposed of during a closed period requiring prior clearance.
For further insights into AU:CHM stock, check out TipRanks’ Stock Analysis page.
